Eventually, with the development of an arsenal of targeted therapies, such as agents that specifically target and destroy IL13Rα2-expressing tumor cells and other tumor associated antigens such as EGFRvIII, personalized treatment protocols can be implemented in conjunction with traditional disease therapies like surgery and radiation to improve the outcome for patients with GBM. The gene discussed is IL13RA2; the disease is glioblastoma.